Table_1_suPAR to Risk-Stratify Patients With Malaria.pdf

Severe malaria (SM) is a leading cause of global morbidity and mortality, particularly in children in sub-Saharan Africa. However, existing malaria diagnostic tests do not reliably identify children at risk of severe and fatal outcomes. Dysregulated host immune and endothelial activation contributes to the pathogenesis of SM. Current research suggests that measuring markers of these pathways at presentation may have clinical utility as prognostic indicators of disease progression and risk of death. In this review, we focus on the available evidence implicating soluble urokinase-type plasminogen activator receptor (suPAR) as a novel and early predictor of severe and fatal malaria and discuss its potential utility for malaria triage and management.

重型疟疾（Severe Malaria, SM）是全球范围内引发高发病率与高死亡率的主要病因之一，在撒哈拉以南非洲的儿童群体中尤为突出。然而，现有的疟疾诊断检测手段无法可靠地甄别出存在重型及致死性转归风险的儿童患者。宿主免疫与内皮激活失调参与了重型疟疾的发病机制。当前研究表明，在患者首次就诊时检测上述通路的相关标志物，可作为疾病进展与死亡风险的预后指标，具备临床应用价值。本综述聚焦于相关现有证据，探讨可溶性尿激酶型纤溶酶原激活物受体（soluble urokinase-type plasminogen activator receptor, suPAR）作为重型及致死性疟疾的新型早期预测标志物的潜力，并讨论其在疟疾分诊与诊疗管理中的潜在应用价值。